Detection of primary drug resistance rates of Mycobacterium tuberculosis complex strains isolated between 2002-2003 years and comparison with the data of 1998-2001 period 2002-2003 yillari arasinda izole edilen Mycobacterium tuberculosis kompleks suşlarinda primer ilaç direnç oranlarinin saptanmasi ve 1998-2001 verileriyle karşilaştirilmasi
Mikrobiyoloji Bulteni, cilt.39, sa.2, ss.153-160, 2005 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 39 Sayı: 2
- Basım Tarihi: 2005
- Dergi Adı: Mikrobiyoloji Bulteni
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.153-160
- Anahtar Kelimeler: Antituberculosis drug susceptibility, Primary drug resistance, Tuberculosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
In this retrospective study, it was aimed to evaluate the primary drug resistance rates of 151 Mycobacterium tuberculosis complex (MTC) strains against primary anti-tuberculosis (anti-TB) drugs, isolated from 2213 tuberculosis suspected patients between January 2002 to December 2003 in our hospital, and also to compare these results with the data obtained from our previous results between January 1998 to December 2001. It has been detected that there was a significant decrease in the susceptibility rates of MTC isolates to all anti-TB drugs both yearly from 1998 to 2003 (p<0.001), and for the total of 1998 and 2003 years period (p<0.029). When only the years 1998 and 2003 were taken into consideration, significant increases were found in any (one or more) combination of the drugs with isoniazid (INH), and only INH resistance rates (p<0.007 and p<0.033, respectively). Thus, naturally there was also an increase in resistance to total any drug resistance (p<0.029). We suggest that strict measures such as "directly observed therapy" should be undertaken in order to prevent development of drug resistance particularly against INH. Regular and continuous screening of anti-TB drug resistance should be accomplished to survey the presence of drug resistant strains in the nation, to define the suitable drug regimens and to evaluate the quality of tuberculosis control programs.